We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Oncodesign and UCB Enter into a Research Collaboration

Oncodesign and UCB Enter into a Research Collaboration

Oncodesign and UCB Enter into a Research Collaboration

Oncodesign and UCB Enter into a Research Collaboration

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Oncodesign and UCB Enter into a Research Collaboration"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Oncodesign has announced that it has entered into a research collaboration and exclusive license option with UCB, a global biopharmaceutical leader specialized in neurology and immunology.

The collaboration will leverage the respective expertise of Oncodesign and UCB to bring innovative therapeutic solutions to patients suffering from neurodegenerative disorders.

Oncodesign will apply its Nanocyclix technology on a kinase target selected by UCB with the aim of discovering potent and selective inhibitors that cross the blood brain barrier.

Oncodesign’s Nanocyclix technology is a proprietary medicinal chemistry platform based on small molecule macrocyclisation that gives access to potent and highly selective kinase inhibitors with attractive physicochemical and ADME properties.

Oncodesign has identified Nanocyclix leads against a broad range of known and unexplored kinases with potential in different therapeutic areas and is engaged in multiple collaborations with pharmaceutical partners.

“This collaboration with UCB further establishes Oncodesign as a major player in the drug discovery field. It strengthens our strategy of early partnering with leading international pharmaceutical companies in fields outside of oncology. This, together with our internal focus on innovative programs against cancer, constitutes a strong basis for addressing major unmet needs in patients and value creation,” said Philippe Genne, Ph.D., chairman and chief executive officer of Oncodesign.

“We are very excited to partner with UCB for the first time on this exclusive research collaboration and license option in the field of neurodegenerative disorders, an area with high unmet needs for a large patient population. This new collaboration demonstrates the growing interest that the pharmaceutical industry has in our Nanocyclix technology. This allows us to discover innovative inhibitors for kinases that are otherwise difficult to address,” said Jan Hoflack, Ph.D., chief scientific officer and head of Oncodesign's discovery activities.